Latest Agenus News & Updates

See the latest news and media coverage for Agenus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Agenus

Cancer immunotherapy company

agenusbio.com
Headquarters
Lexington, United States
Founded year
1994
Company type
Public company
Number of employees
200–500
Industry
Pharmaceuticals

Last updated

Latest news about Agenus

In short: Agenus secured up to $340 million in private placement funding and advanced its Phase 3 ROBBIN trial for colorectal cancer immunotherapy.

Company announcements

Agenus

Agenus reports 33% three-year survival in MSS mCRC

The Phase 1b BOT+BAL data show 21.2-month median overall survival and a survival curve plateau.

Unlock all announcements with a

Media coverage

AFP

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT...

Unlock all articles with a

Never miss news about Agenus

Track Agenus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agenus competitors & trending companies

Browse news for competitors to Agenus and other trending companies.